Dr Andrew Epstein, Prof Richard Schilsky and Dr Geertjan van Tienhoven comment on data, during a press conference at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, from the PREOPANC-1 trial.

This was a phase III randomised trial in which patients with resectable pancreatic cancer received 10 weeks of chemoradiotherapy prior to surgery, or immediate surgery alone.

For more on these results, watch Dr van Tienhoven present this data in a press conference here, watch Dr van Tienhovens interview with ecancer here, or read news coverage here.